News & Perspective

Nov 17, 2004

Nov 17, 2004

Clinical trials of human H5N1 flu vaccine to start soon

(CIDRAP News) – Clinical trials of a vaccine designed to keep the H5N1 avian influenza virus from sparking a human flu pandemic will begin early in 2005, the head of the National Institute of Allergy and Infectious Diseases (NIAID) said this week.

Feb 17, 2005

Feb 17, 2005

Report: WHO to suggest stockpiling H5N1 flu vaccine

(CIDRAP News) – The World Health Organization (WHO) is preparing to recommend that governments consider stockpiling vaccines against the H5N1 avian influenza virus now, rather than waiting until a human flu pandemic emerges, according to a story published online today by New Scientist magazine.

Mar 25, 2005

Mar 25, 2005

Two studies boost hopes for pandemic flu vaccines

(CIDRAP News) – Two new studies give reason to hope that vaccines prepared in advance could be of some help in combating an influenza pandemic.

Apr 13, 2005

Apr 13, 2005

Pandemic flu virus from 1957 mistakenly sent to labs

(CIDRAP News) – The revelation that samples of the influenza virus that caused the flu pandemic of 1957-58 were inadvertently sent to thousands of laboratories has raised fears of a new pandemic and triggered an urgent effort to destroy the samples.

Apr 24, 2006

Apr 24, 2006

Study cites gaps in Europe's flu pandemic plans

(CIDRAP News) – European countries' plans for coping with an influenza pandemic are generally good but have a number of gaps, including a lack of detail on distribution of drugs and supplies, according to an analysis published last week by The Lancet.

Sep 19, 2006

Sep 19, 2006

Sanofi tests H7N1 flu vaccine for pandemic readiness

(CIDRAP News) – Sanofi Pasteur today announced the start of the first clinical trial of an H7N1 influenza vaccine, intended to guard against the threat of a pandemic caused by H7 strains of avian influenza.

Current concern about a flu pandemic focuses mainly on the H5N1 avian flu virus, which has infected at least 247 people and killed 144. But H7 avian flu viruses have caused a number of mild illness cases and one death in the past 3 years.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Feb 03, 2009

Feb 03, 2009

Experts weigh new H5N1 vaccine strategies

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

Apr 02, 2010

Apr 02, 2010

WHO says H1N1 still active in parts of tropics

(CIDRAP News) – The World Health Organization (WHO) yesterday reported moderately active pandemic influenza activity in parts of the tropical regions of Asia, the Americas, and Africa, as well as influenza B activity in much of East Asia.

Pages

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»